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RESEARCH ARTICLE Open Access
Burden of early, advanced and metastatic
breast cancer in The Netherlands
G. T. Vondeling1* , G. L. Menezes3, E. P. Dvortsin1, F. G. A. Jansman4,5, I. R. Konings6, M. J. Postma1
and M. H. Rozenbaum2
Abstract
Background: The aim of this study was to estimate the total economic and health related burden of breast cancer
in the Netherlands.
Methods: Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer
Registry and were used to calculate the economic and health related burden of breast cancer for overall, DCIS
(stage 0), early- (stage I), locally advanced- (stage II-III) and metastatic- (stage IV) breast cancer by age groups and
by year (if applicable).
Results: The overall incidence of breast cancer increased from 103.4 up to 153.2 per 100,000 women
between 1990 and 2014. The increase was driven by DCIS and early breast cancer as the incidence of
locally advanced and metastatic breast cancer remained stable. Between 1990 and 2014, ten-year overall
survival rates increased from 87% to 93% for early breast cancer, 41% to 62% for locally advanced- and
from 6% to 9% for metastatic disease. Annually, breast cancer in the Netherlands is responsible for
approximately 3100 deaths, 26,000 life years lost, 65,000 Disability Adjusted Life Years (DALYs) and an
economic burden of €1.27 billion.
Conclusions: This study provides a comprehensive assessment of the burden of breast cancer and subsequent trends
over time in the Netherlands.
Keywords: Breast cancer burden costs incidence prevalence mortality early advanced metastatic
Background
Breast cancer is the most common cancer and lead-
ing cause of cancer-related mortality amongst
women worldwide [1, 2] .Together with lung, colo-
rectal and prostate cancer, breast cancer contributes
to half of the overall burden of cancer mortality in
Europe [3] .In Europe approximately 500,000
women are diagnosed with breast cancer annually
and in 2012, breast cancer cases were responsible
for a third of all cancer related deaths (131,259)
[4]. The incidence and prevalence of breast cancer
increased over the past decades due to the
progressive nature of the disease and the aging
population in Western countries [1] .In 2010, the
lifetime risk of developing breast cancer was 1 in
6.6 women in the Netherlands while the lifetime
risk of breast cancer death was 1 in 27 [5] .Further-
more, it has been shown that the Netherlands has a
breast cancer related Disability Adjusted Life-Year
(DALYs) burden of approximately of 1100 DALYs
per 100,000 women [6].
Several previous studies aimed to assess the burden
of breast cancer. However, to our knowledge, there is
currently no study available assessing both the eco-
nomic and health Burden of Disease (BoD) stratified
by stage using data from a national cancer registry
over a 24 year period [7, 8] .Stratification by stage of
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diagnosis is necessary, since the burden of disease dif-
fers between disease stages [7] .Mapping the stage
stratified breast cancer burden over time also enables
adequate evaluation of policy implementation and de-
cision making, for instance regarding the mammo-
graphic screening program [9] .In addition, this will
provide new insights into the difference in morbidity
and mortality between early, locally advanced and
metastatic breast cancer.
The aim of this study is to describe the total health
and economic related burden of breast cancer in the
Netherlands. The total burden of breast cancer is
expressed in economic costs per year, incidence,
prevalence, survival, mortality, life-years lost and
DALYs. The results of this study can be used to fa-




Breast cancer incidence, prevalence, survival and
mortality data between 1990 and 2014 were obtained
from the Netherlands Comprehensive Cancer
Organization (IKNL) and the National Cancer Regis-
try (NCR) [10] .As survival data within this database
is generated in cohorts, most recent 10-year survival
was available until 2009. Additionally, data was avail-
able for up to 4-year survival in the latest cohort
(2010–2013). Tumors in this registry are coded
according to the International Classification of Dis-
eases for Oncology (ICD-O). Regarding multiple pri-
mary cancers, the registry follows the guidelines
developed by the International Agency for Research
on Cancer (IARC) and the International Association
of Cancer Registries (IACR). In this study we differ-
entiate between early, locally advanced and meta-
static breast cancer based on the Tumour Node
Metastasis (TNM) classification and IACR guidelines
[11, 12] .Stage 0 (DCIS) and Stage I were defined as
early breast cancer, stages II to III as locally ad-
vanced breast cancer, and stage IV was labeled as
metastatic breast cancer. In the performed analyses
(see below), the results are reported per separate
stage where possible. This distinction was made
based on the differences in treatment guidelines with
recommendations ranging from breast-conserving
surgery to mastectomy, radiation therapy, chemo-
therapy, hormone therapy, or a combination of dif-
ferent treatments in stage IV [13, 14].
Incidence, prevalence, and mortality
Incidence, prevalence and mortality data were both
obtained in crude rates (absolute number of cases in
the Netherlands), and in European Age Standardized
Rates (ESR) (cases per 100,000 women, corrected by
age for the European geographic composition). DCIS
is not included in the survival analysis. Up to 10-year
overall survival data (over the period 1989–2009)
were available. For the most recent data a sub-
analysis consisting of 4-year survival data from the
period 2010–2013 was included. When applicable, re-
sults are presented in five-year age groups starting at
the age of 15 (e.g. 15–19, 20–24, etc.) up to 95, after
which the age band is open including all subject aged
95 years and older.
DALY burden
The Disability Adjusted Life-Year (DALY) is a measure
to express the BoD. DALYs represent the number of
healthy life lost due to a disease or risk factor. One
DALY can be regarded as 1 lost year of “healthy
life”. It is calculated by adding the years of life lost
due to premature mortality (YLL) to the years lived
with disability (YLD, morbidity). YLL regards the
sum of years that a person would have lived if the
individual would not have the current disease under
study and was based on the average life expectancy
of women in the Netherlands [15] .YLD expresses
the consequences of living with a less than perfect
health condition, and is estimated based on the
length of time with that condition and the corre-
sponding disability weight. The parameters used to
estimate DALYs are mortality, incidence, average
duration to death or cure from breast cancer, the
disability weight of living with breast cancer and the
age at diagnosis. Based on the EUROCARE-4 study,
we estimated that the median duration of cancer
until patients were either cured or deceased was
4.3 years [16] .This number was subsequently used
to calculate the YLL. The Disability weight was
assessed at 0.38, that was derived from Disability
Weights for Diseases in the Netherlands study, being
the average disability weight of all disease stages,
weighted by its duration and cure rate [17] .A
discount rate of 1.5% was applied to both YLL and
YLD, which is the standard discount rate in the
Netherlands for discounting health outcomes and
utilities. Additionally, the DALY burden was calcu-
lated without inclusion of DCIS. The metrics on
how DALYs were calculated can be found in
Additional file 1.
Economic burden
The total healthcare expenditure due to breast
cancer in the Netherlands was obtained from the
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cost of illness database by the national institute
for public health (RIVM). Data were available for
2003, 2005, 2007 and 2011. This database is a
product of the Dutch government and was used
for policy and healthcare decision making. The
costs include public healthcare and prevention,
costs for 1st line care, hospital & medical profes-
sional care, elderly care, drugs, management and
costs of other healthcare providers, as derived
from the national cost of illness database [18] .The
costs of breast cancer in 2014 were estimated by
extrapolating those from 2011 using Dutch Cus-
tomer Price Index (CPI) inflation rates [19] .Prod-
uctivity losses due breast cancer-related morbidity
and mortality in the Netherlands were estimated
using the human capital approach (more details on
the exact methods and equations used to calculate
these indirect non-medical costs can be found in
Additional file 1). All prices in this study are
expressed in 2014 Euros.
Sensitivity analysis
Univariate sensitivity analysis was used to investigate
the sensitivity of the base-case estimates to variation
in several parameters. The gross domestic product
growth rate, used for the prediction of future growth
rate, was varied to 0%, 1.5% and 3.5%, to account
for uncertainty over future growth in the Dutch
economy. The discount rate for costs was varied be-
tween 2% and 6%. Female Gross Labor participation
was adjusted to match the amount of men, to ac-
count for future emancipation. Work-Absence rates
were varied by ±10% to investigate the sensitivity of
this estimate on productivity losses due to morbidity.
In addition, the effect of extending the retirement age
from 65 to 66 and 67 was explored, to account for
potential changes in the official retirement age in the
Netherlands. For productivity losses due to mortality,
we varied the results by using the friction cost
method, which only takes the friction period of 85
calendar days in consideration for potential loss of
productivity [20].
Results
Absolute cases, incidence, and prevalence
In total 320,179 women were diagnosed with breast
cancer in the Netherlands between 1990 and 2014.
The absolute overall number of cases per year in-
creased from 8233 in 1990 up to 16,688 in 2014 (see
Table 1 and Appendix Figure 1). This increase was
mainly due to the 231% increase in cases of early
breast cancer (including DCIS) from 2682 to 8869.
During the same period, the number of locally ad-
vanced breast cancer cases also increased by 40%
and metastatic disease increased by 43%. When ex-
cluding DCIS from the analysis the absolute overall
number of incident breast cancer cases increased
from 7913 in 1990 to 14,541 in 2014.
The overall incidence increased from 103/100,000
in 1990 to over 153/100,000 women in 2014 (Table
1 and Fig. 1). The increase in the incidence was
mainly attributable to an increase of early breast
cancer diagnosis (from 34.6/100,000 to 82.7/100,000
women). In particular the incidence of DCIS in-
creased by 386% (from 4.2/100,000 to 20.4/
100,000). Overall the incidence of locally advanced
breast cancer was stable (3% increase). However,
within more advanced disease stages, there were
large differences with a decline of 5% for both
stage II and stage IIIb/c and an increase of 115% in
stage IIIa. Finally, the incidence of metastatic
breast cancer (stage IV) remained stable during the
study period.
The 5-year prevalence of breast cancer increased
by 77% (from 41,476 in 1995 towards 73,261 in
2014). The 10-year prevalence (available from 2000
Table 1 European Standardized Incidence Rates of breast cancer per stage of diagnosis for the Netherlands between 1990 and 2014, along
with the absolute number of cases between brackets
Early Breast Cancer Advanced Breast Cancer Metastatic Overall
Period DCIS I Total II IIIa IIIb/c Total IV DCIS (0) - IV
1990 4.2 (320) 30.4 (2362) 34.6(2682) 51.7 (4151) 3.9 (301) 6.5 (556) 61.1(5008) 6.7 (543) 103.4 (8233)
1995 10.0 (793) 43.4 (3501) 53.4(4294) 51.9 (4425) 3.5 (294) 5.3 (534) 60.7(5253) 5.4 (493) 119.5 (10040)
2000 12.2 (1059) 48.1 (4262) 60.3(5321) 58.5 (5355) 3.6 (324) 4.9 (536) 67(6215) 5.6 (562) 132.9 (12098)
2005 12.3 (1229) 50.4 (4738) 63.7 (5967) 49.7 (4937) 9.5 (903) 6.9 (752) 66.1 (6592) 5.7 (612) 135.5 (13171)
2010 19.3 (1877) 60.3 (6083) 79.6 (7960) 45.8 (4884) 9.0 (895) 7.6 (844) 62.4 (6623) 5.1 (573) 147.1 (15156)
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Fig. 1 European Standardized breast cancer incidence rates per 100,000 women stratified by stage of diagnosis between 1990 and 2014 for the
Netherlands. Vertical lines represent changes in TNM
Fig. 2 Proportionate stage at diagnosis per age group for the year 2014
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onwards) increased by 58% (from 78,892 to
124,996).
Proportional distribution by stage over time and by age
The proportion of women diagnosed with early breast
cancer (including DCIS) increased from 33% in 1990
to 54% in 2014. During the same period, we observed
a reduction in the proportion of locally advanced
breast cancer (from 60% to 42%) and metastatic dis-
ease (from 6% to 4%). Additional analysis showed that
the proportion early breast cancer increased from
31% in 1990 to 47% in 2014 while locally advanced
and metastatic decreased from 63% and 7% to 48%
and 5% respectively when DCIS was excluded.
Figure 2, shows the proportional distribution by stage
at diagnosis per age group for 2014. It clearly shows
that the proportion of early stages of breast cancer is
highest in the group of women aged between 50 and
74, which corresponds to the breast cancer screening-
bracket in the Netherlands (50 to 75 years). Also the
incidence (in absolute annual numbers) is higher in
the age groups within the screening brackets (Fig. 3).
This is also true for locally advanced and metastatic
incidence. The exception is that the number of cases
of locally advanced disease is higher in the 45 to
49 year old group compared to the age groups within
the 55 to 75 years range.
Fig. 3 Incidence of early and advanced breast cancer by age for 2014
Fig. 4 Ten-year overall survival of early and advanced breast cancer patients
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Survival rates
Figure 4 shows the overall survival for early, locally ad-
vanced and metastatic breast cancer between 2003 and
2009 (6th TNM edition). It clearly shows the large impact
of stage at diagnosis. For example, 5 years after diagnosis
the overall survival was 98% for early breast cancer, 85% for
locally advanced and 22% for metastatic disease. After
10 years, these numbers are 94%, 75% and 9%. Survival data
specified per cancer stage from Ia to stage IV is available in
the Additional file 1.
An increase in survival was observed for all stages
of breast cancer compared to historical survival data
(see Additional file 1: Tables S1-S5). Accordingly, the
most recent data in the 7th TNM edition show a
slight increase in survival. Although our data analysis
regarded a limited period of four-years (2010–2014),
we observe an increase in overall survival of 1% for
early breast cancer, 1% locally advanced and 4% meta-
static breast cancer in comparison with the previous
survival data from the 6th TNM edition.
Fig. 5 Mortality in the Netherlands between 1990 and 2014
Fig. 6 Burden of breast cancer in the Netherlands expressed in Disability Adjusted Life years (DALY) which consist of life-years lost due to
early mortality (YLL) and life-years lost due to morbidity (YLD)
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Deaths, life years and DALYs lost
In total 84,282 women died of breast cancer in
the Netherlands between 1990 and 2014. The
number of deaths of 3666 was highest in 1999
and decreased to 3014, i.e. by 18%, in 2014 (see
Fig. 5). Corrected for age and for the demo-
graphic composition of the European population,
a more significant decrease of 41% was observed
(from 39.17 per 100,000 women per year in 1991
to 23.01 per 100,000 in 2014). The total number
of life-years lost due to breast cancer between
1990 and 2014 in the Netherlands was estimated
at 1.35 million. Despite the rising incidence in
breast cancer, the total number of life-years lost
per year decreased by 15.6% during this same
period (Additional file 1: Table S6).
The DALY burden peaked in 2010 when breast cancer
was accountable for a total of 68,500 DALYs in the
Netherlands (Fig. 6). From this total, 50,000 where at-
tributable to life years lost from early mortality (YLL)
and 18,500 from disability (YLD). Since 1990, the YLL
gradually decreased from 45,900 to 38,600, while the
YLD increased from 13,000 to 26,000 which outweighs
the reduction in YLL. Excluding DCIS from the analysis
resulted in a decrease in the YLD leading to a total bur-
den of 61,600 DALYs in 2014 versus 65,000 with inclu-
sion of DCIS. In terms of the age distribution, patients
aged 45–65 are accountable for the highest number of
DALYs, which is directly correlated with the incidence
and mortality of the disease.
Healthcare costs and productivity losses
The total healthcare costs of breast cancer in the
Netherlands increased from €199 million in 2003
up to €692 million in 2011 (Table 2). Costs in
most categories increased in absolute terms,
although regarding the proportional expenditure
per year, we see that only the costs related to
hospital and medical professional care increased.
The costs due to hospital and medical professional
care accounted for €96.5 million (49% of the total
budget) in 2003 and were €542.6 million (78% of
the total budget) in 2011. Proportionate drug
expenditure was stable between 2003 and 2007
(13%), but dropped to 7% between 2007 and 2011.
The healthcare expenditure per age group (Fig. 7)
is highly correlated to the incidence per age groups
(Fig. 3). Total cost of productivity losses due to
morbidity and mortality cumulated to €260 million
and €243 million annually, respectively (Table 3).
Combining the productivity losses with the total
estimated healthcare expenditure, the total eco-
nomic due to burden of breast cancer cumulates to
€1.27 billion for 2014.
Sensitivity/scenario analyses
Additional file 1 summarizes the results of the sensi-
tivity analysis for the calculation of productivity
losses due to morbidity and early mortality. It shows
that the estimated productivity losses due to morbid-
ity were between €258 and €334.6 million annually.
Productivity losses due to mortality ranged between
€221 million and €323 million annually. A scenario
analysis that took future emancipation into account
by matching the female gross labor participation to
that of men, resulted in a total productivity of €335
million due to morbidity and €317 due to early mor-
tality. Applying the friction cost rather than the hu-
man capital approach resulted in a productivity loss
of €43 million due to morbidity and €6 million due
to early mortality.
Discussion
This is the first study in The Netherlands to
examine the burden of breast cancer in terms of
incidence, prevalence, survival, deaths, life years
Table 2 Healthcare costs of breast cancer in the Netherlands in Million Euro’s
Expenditure 2003 2005 2007 2011 Estimates 2014
Public healthcare and prevention 41.8 (21%) 44 (18%) 47.7 (11%) 63.1 (9%) 9%
1st line care 4.6 (2%) 5.1 (2%) 7.1 (2%) 7.5 (1%) 1%
Hospital & medical professional care 96.5 (49%) 129.8 (54%) 280.7 (65%) 542.6 (78%) 78%
Elderly Care 19.3 (10%) 18.5 (8%) 19.1 (4%) 17.8 (3%) 3%
Drugs 26.7 (13%) 32.6 (13%) 57.1 (13%) 45.7 (7%) 7%
Other healthcare providers 3.1 (2%) 3.3 (1%) 5.7 (1%) 2.7 (0%) 0%
Management 6.7 (3%) 8.9 (4%) 12.2 (3%) 12.5 (2%) 2%
Total Costs in Million (€) 199 (0.31%a) 243 (0.36%a) 430 (0.58%a) 696 (0.78%a) 768 (0.80%a)
aPercentage of healthcare budget
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lost, DALYs, healthcare and productivity losses
stratified by breast cancer stage and age using data
from a national registry. This study shows an
overall increase in incidence of breast cancer be-
tween 1990 and 2014 which was mainly attribut-
able due to an increase in the incidence of early
breast cancer. While the incidence increased the
mortality rates decreased for both early, locally
advanced and metastatic breast cancer during the
same time period. Despite the promising trends in
survival breast cancer remains the leading cause of
cancer related deaths amongst women. The rising
incidence corresponds with an increase in the total
economic burden of breast cancer, for which the ma-
jority of the costs concern healthcare costs followed
costs for productivity losses due to morbidity and
early mortality.
Although DCIS (stage 0) may not be considered
as breast cancer in every country, it still needs
therapeutic intervention (and in some countries
hormonal treatment), has an impact on the quality
of life of the patients and is associated with (treat-
ment) costs. Therefore DCIS was included in the
analysis. During the study period the incidence of
early stage breast cancer increased while the inci-
dence of locally advanced and metastatic breast
cancer remained stable. The biggest rise in inci-
dence was seen within DCIS followed by stage I
diagnosis. This discrepancy could partly be
explained by the introduction and continuous
improvement of the national mammographic
screening program, resulting in an increasing
number of women diagnosed with early stage breast
cancer [21, 22] .These early breast cancer cases
might, however, remain asymptomatic throughout a
woman’s life. If such a patient undergoes unneces-
sary treatment, with its associated morbidity, this is
considered as overdiagnosis [21, 22] .In the litera-
ture, estimates on breast cancer cases from overdi-
agnosis range between 0% and 36% of the total
diagnosed cases [21, 22] .In contrary to the rising
incidence the breast cancer related mortality de-
creased between 1990 and 2014. Although the avail-
able 10-year survival data was limited to 2009, this
data is still relevant as is shows ongoing trends
regarding decreasing mortality. This decrease can
be explained by the improved diagnostics, better
treatment options including radiotherapy and tar-
geted therapies, and the introduction of more ef-
fective drugs during this period [23, 24] .The
increase in economic burden was mainly caused by
a rise in costs related to hospital and medical pro-
fessional care. Proportionate drug expenditure was
small and stable at 13% between 2003 and 2007,
and dropped further down to 7% of the total ex-
penditure towards breast cancer between 2007 and
Table 3 The total economic burden caused by breast cancer in
the Netherlands (Human Capital Approach)
Healthcare Expenditure towards breast cancer in 2014 €768 million
Productivity Losses due to morbidity €260 million
Productivity Losses due to mortality €243 million
Total economic burden €1271 million
Fig. 7 Proportionate healthcare spending of breast cancer by age groups in the Netherlands
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2011. Although data on healthcare expenditure and
costs for breast cancer were limited to 2011, this
data is still relevant as it shows trends over time
regarding increasing healthcare costs that are still
ongoing and relevant for nowadays situation. Since
the healthcare costs have increased in general over
the last 6 years, our cost estimates might be con-
servative. The increase seen in indirect non-medical
costs was attributable to and corresponding with
the increase in incidence. The productivity losses
due to morbidity where main driver of the
increasing burden over time, even when DCIS was
excluded from the analysis.
Comparison to other studies
Similar to our findings, other studies also showed that
incidence of breast cancer is increasing. Between
1990 and 2013, age standardized incidence rates of
invasive breast cancer increased by 17% globally (44
to 52 per 100,000) [8] .However, a large difference
between developing countries (a 48% increase from
28 to 40 per 100,000) and developed countries (a 8%
increase from 70 to 75 per 100,000) was observed [8,
25] .Our results show an increase of 34% (from 99 to
133 cases per 100,000) during the same period. Prior
studies on recent trends in Belgium, Norway and
Spain sho4wed a similar increase in incidence from
the 1990s and onwards [26–28] .Belgium has the
highest incidence in Europe with 147.5 per 100,000
women in 2012, compared with 131.3 per 100,000 in the
Netherlands. Together with Germany (122.0), the UK
(129.2), Denmark (142.8) and Finland (121.0) these coun-
tries are leading in Europe [3] .Southern European coun-
tries, such as France, Spain, Portugal and Italy along with
Norway and Sweden fell in the incidence range between
78.2 and 119.6 per 100,000 women and the lowest inci-
dence was seen in eastern Europe were incidence rates
were below 78.1 per 100,000 [3].
Next to the extensive screening program, the more
significant increase in the incidence in the Netherlands
compared to other developed countries might be
explained by risk factors as late motherhood and low
number of off-spring in the Netherlands as compared to
other countries [29–33].
Breast cancer survival rates vary greatly between
European countries, which could be attributable to
the differences in stage of diagnosis in various
countries. The Netherlands is leading in terms of
survival when comparing out data to other coun-
tries in Europe [34] .For example, the one-year
survival for stage IV disease between 2003 and
2009 was 69%, while it ranged between 53% and
67% in other European countries. Unfortunately,
we were not able to show the difference between
specific tumors types such as hormone receptor
positive (HR+) or human epidermal growth factor
2 positive (HER2+) tumors as these specific data
were not available. Nevertheless, it is known that
the overall survival of women diagnosed with HR
+/HER2+ is better when compared to triple nega-
tive breast cancers, since HR+/HER2+ tumors may
respond to targeted therapies. Further research
could investigate the impact of these specific
tumor types on the burden of breast cancer such
as incidence and survival. Although this would not
change the overall burden of the disease, it will
give us more understanding in inequality in
burden between different types of breast cancer,
also providing insights for further research and
recourse allocation.
Limitations
Although we were able to stratify most of the re-
sults by age and cancer stage, this was unfortu-
nately not possible for the economic burden due to
the unavailability of these data. Data were only
available on total healthcare expenditures and could
not stratified on expenditures by stage of diagnosis.
Apart from availability of data, the changing health
related burden over time is difficult to assess, as
the TNM classification changed over time. The
switch from the 5th to the 6th TNM classification,
for example, resulted in a shift from stage IIa to
stage I as well as a shift from stage IIb to stages
III, which complicates the comparison of the bur-
den over time. To overcome these, we grouped the
stages by early, locally advanced and metastatic
breast cancer, but also presented all data for the in-
dividual stages. Another limitation was related to
the estimation of the proportion of health-care ex-
penditure. Since 2009 oncology drugs are financed
from the hospital budget instead of the general
drug budget limiting the transparency of the actual
drug costs due to breast cancer.
Conclusion
This study provides a comprehensive assessment of
the burden of breast cancer and subsequent trends
over time in the Netherlands. Despite the promising
trend of increase in survival after breast cancer diag-
nosis, this study shows that the BoD due to breast
cancer remains significant. Furthermore, our study
shows large differences in the incidence and mortality
due to early, locally advanced, and metastatic breast
cancer in the Netherlands.
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Appendix
Additional file
Additional file 1: Productivity losses due breast cancer-related morbidity
and mortality. (DOCX 51 kb)
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